Pharmaceuticals, Biotechnology and Life Sciences
UK-based Hikma Pharmaceuticals posted higher annual revenue and strong performance in its injectables segment, but investors reacted negatively to its outlook, sending shares to a three-year low.
GlaxoSmithKline has entered into an agreement to acquire Canadian clinical-stage biotech 35Pharma Inc. for $950 million in cash, expanding its respiratory and cardiovascular pipeline, according to regulatory filings and the company’s announcement.
Gilead Sciences has agreed to acquire cancer therapy developer Arcellx Inc. in a transaction valued at up to $7.8 billion, deepening its footprint in cell therapy for blood cancers
Over the past decade, antibody-drug conjugates (ADCs) have emerged as a high-impact class of cancer therapies, blending the selectivity of antibodies with the potency of cytotoxic payloads. But as the modality matures, a structural tension is becoming clear: should innovation focus on chemical escalation of payloads and linkers, or on biological precision of target engagement?
The global drug discovery network ELRIG has appointed Dr Kelly Gray and Dr Elaine Duncan to its Board, reinforcing leadership across scientific programming and early career initiatives,
Antibody-drug conjugates (ADCs) continue to evolve as one of the most promising approaches in targeted cancer therapy, yet the fundamental…
Sandoz posts 7% revenue growth for 2025, driven by 15% biosimilars expansion, and guides for accelerated sales and margin growth in 2026.
Promatix Biosciences presents preclinical data on PBS293-MMAE, a first-in-class bispecific ADC targeting EGFR and EphA2 in colorectal cancer.
South Korean pharmaceutical manufacturers are rapidly expanding capacity to support manufacturing of long‑acting obesity shots, signalling deeper integration with global…
With semaglutide patents nearing expiry in key markets, Indian manufacturers and partners are mobilizing to introduce lower‑cost GLP‑1 alternatives, tapping…